Last Updated: November 17, 2026

Zidesamtinib - Generic Drug Details

« Back to Dashboard


What are the generic sources for zidesamtinib and what is the scope of patent protection?

Zidesamtinib is the generic ingredient in one branded drug marketed by Nuvalent and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for zidesamtinib
Generic Entry Date for zidesamtinib*:
Constraining patent/regulatory exclusivity:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for zidesamtinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nuvalent JIDEYTRO zidesamtinib TABLET;ORAL 220185-002 Jul 22, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Nuvalent JIDEYTRO zidesamtinib TABLET;ORAL 220185-001 Jul 22, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Nuvalent JIDEYTRO zidesamtinib TABLET;ORAL 220185-001 Jul 22, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Nuvalent JIDEYTRO zidesamtinib TABLET;ORAL 220185-002 Jul 22, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Nuvalent JIDEYTRO zidesamtinib TABLET;ORAL 220185-001 Jul 22, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Nuvalent JIDEYTRO zidesamtinib TABLET;ORAL 220185-001 Jul 22, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for zidesamtinib

Country Patent Number Title Estimated Expiration
Australia 2021268664 ⤷  Start Trial
Brazil 112022022535 COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE TRATAMENTO DE CÂNCER, MÉTODO DE INIBIÇÃO SELETIVA, MÉTODO DE REDUÇÃO DE UM NÍVEL DE ROS1 OU ALK ⤷  Start Trial
Canada 3179700 AGENTS CHIMIOTHERAPEUTIQUES A BASE D'ETHERS MACROCYCLIQUES HETEROAROMATIQUES (HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS) ⤷  Start Trial
Chile 2022003045 Quimioterápicos de éter macrocíclico heteroaromático solicitudes relacionadas ⤷  Start Trial
China 115916754 杂芳族大环醚化学治疗剂 (Heteroaromatic macrocyclic ether chemotherapeutic agents) ⤷  Start Trial
European Patent Office 4146626 AGENTS CHIMIOTHÉRAPEUTIQUES À BASE D'ÉTHERS MACROCYCLIQUES HÉTÉROAROMATIQUES (HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Zidesamtinib Market Dynamics and Financial Trajectory

Last updated: September 8, 2026

Zidesamtinib, also known as NVL-655, is Nuvalent’s investigational, brain-penetrant, next-generation ALK tyrosine kinase inhibitor for ALK-positive non-small-cell lung cancer. It has no FDA approval, commercial revenue, Orange Book listing, or generic competition. Its value depends on clinical differentiation from lorlatinib and other ALK inhibitors, particularly in patients with ALK resistance mutations and central nervous system disease.

Nuvalent’s financial profile remains that of a clinical-stage biotechnology company: no product sales, recurring research and development losses, and dependence on equity financing and cash reserves until a potential approval, partnership, or acquisition.

What is zidesamtinib and which market does it target?

Zidesamtinib is designed to selectively inhibit ALK while limiting activity against TRKB, a target associated with central nervous system and cognitive adverse effects seen with some ALK inhibitors. Nuvalent is developing the drug for previously treated ALK-positive metastatic NSCLC, including tumors with resistance mutations after prior ALK tyrosine kinase inhibitor therapy.

Attribute Zidesamtinib
Developer Nuvalent, Inc.
Development code NVL-655
Drug class Oral, next-generation ALK tyrosine kinase inhibitor
Main indication ALK-positive metastatic NSCLC
Development stage Phase 1/2 clinical development
Key trial ALKOVE-1
FDA approval None
Product revenue None
Orange Book status No listing
Generic or biosimilar competition None
Primary commercial issue Differentiation after prior ALK inhibitor treatment

The commercial opportunity is concentrated in a biomarker-defined population. ALK rearrangements occur in roughly 3% to 7% of NSCLC cases, with the highest frequency in younger patients and people who have never smoked. The addressable population is smaller than the overall lung-cancer market, but treatment duration can be long and targeted therapies generally command premium pricing.

What is the development and FDA status of zidesamtinib?

Zidesamtinib is being evaluated in the ALKOVE-1 study, a global Phase 1/2 trial in patients with advanced ALK-positive solid tumors, including NSCLC. The study assesses safety, dose selection, pharmacokinetics, and antitumor activity in patients previously treated with ALK inhibitors (ClinicalTrials.gov, n.d.).

Nuvalent has positioned zidesamtinib around three clinical attributes:

  1. Activity against treatment-emergent ALK resistance mutations.
  2. Penetration into the central nervous system.
  3. A differentiated safety profile through ALK selectivity and reduced TRKB inhibition.

FDA approval has not been granted. No New Drug Application approval date, Prescription Drug User Fee Act action date, or commercial launch date has been publicly established in the core development disclosures reviewed.

What FDA regulatory milestones has zidesamtinib reached?

The regulatory value of zidesamtinib is tied to the FDA’s willingness to recognize an unmet need in post-ALK-inhibitor disease. A potential Breakthrough Therapy Designation, Fast Track designation, or priority review could shorten development and review timelines, but none substitutes for confirmatory efficacy and safety data.

The most commercially important future milestones are:

Milestone Commercial effect
Dose selection Determines whether the program can enter registrational development
Clear response data in resistant disease Supports accelerated or conventional approval strategy
Durable intracranial activity Improves positioning against lorlatinib and chemotherapy
Registrational trial initiation Reduces development-stage risk
NDA acceptance Establishes a defined FDA review timeline
FDA approval Creates the first revenue opportunity
Label expansion Increases the treated population and commercial value

How does zidesamtinib compare with lorlatinib and other ALK inhibitors?

Zidesamtinib enters a market led by established ALK inhibitors, not an untreated market. The relevant competitors include lorlatinib, alectinib, brigatinib, crizotinib, and ensartinib where available. Lorlatinib is the most important direct comparator for treatment-refractory patients because it has strong activity against several ALK resistance mutations and substantial central nervous system penetration.

Drug Company Position in treatment Competitive relevance
Lorlatinib Pfizer First-line and later-line ALK-positive NSCLC Strong CNS activity; safety and resistance management remain key issues
Alectinib Roche Major first-line standard Broad use and long clinical history
Brigatinib Takeda First-line and later-line use Established efficacy and physician familiarity
Ensartinib Innovent and Hansoh Regional and potentially broader use Competes on efficacy, CNS activity, and tolerability
Zidesamtinib Nuvalent Investigational later-line and potentially earlier-line therapy Differentiation depends on resistant-mutation coverage and safety

Zidesamtinib’s commercial thesis is strongest if it demonstrates meaningful activity after lorlatinib or other next-generation ALK inhibitors. A drug that only duplicates existing first-line efficacy would face a higher commercial barrier because physicians already have established therapies and treatment guidelines.

What financial trajectory does zidesamtinib have?

Zidesamtinib currently generates no product revenue. Nuvalent’s financial trajectory is therefore determined by clinical spending, capital-market access, and the probability-adjusted value of its pipeline rather than sales growth.

Revenue profile

Nuvalent has no approved product and no reported commercial sales from zidesamtinib. Any current corporate revenue is not product revenue from zidesamtinib. The program remains an expense driver through clinical trials, manufacturing, regulatory preparation, and medical affairs planning.

The financial trajectory can be summarized as follows:

Period Financial position
Pre-approval No product sales; research and development losses
Regulatory development Higher trial, manufacturing, and regulatory costs
Approval First potential product revenue
Early launch High commercial investment and payer access costs
Post-launch Revenue depends on label, treatment line, duration, and competitive differentiation

Nuvalent’s annual filings report the financial characteristics of a development-stage biotechnology company: operating losses, research and development expenditure, and reliance on cash, marketable securities, equity offerings, and other financing sources (Nuvalent, Inc., 2024).

What determines Nuvalent’s valuation?

The largest valuation variables are:

  • Probability of successful Phase 2 and registrational development.
  • Depth and durability of responses after prior ALK inhibitors.
  • Intracranial response rates and duration.
  • Incidence of neurocognitive, metabolic, cardiovascular, and other class-related adverse events.
  • Ability to support a regulatory label in post-lorlatinib disease.
  • Commercial pricing and payer restrictions.
  • Competitive timing for lorlatinib, ensartinib, and other next-generation ALK therapies.
  • Cash runway through the next major clinical readout.

Zidesamtinib is the central value driver in Nuvalent’s ALK franchise, but the company also has neladalkib, or NVL-520, an investigational ROS1 inhibitor. The second program can diversify pipeline risk, but it also increases research and development spending before either asset produces revenue.

What patents protect zidesamtinib?

Zidesamtinib is protected primarily through composition-of-matter, pharmaceutical composition, formulation, and method-of-use patent filings. The exact commercial exclusivity period depends on issued claims, terminal disclaimers, patent-term adjustment, patent-term extension, and the jurisdictions in which claims survive examination and opposition.

Because zidesamtinib is not FDA-approved, it has no Orange Book patent listing. There is also no Paragraph IV challenge directed to an approved product and no authorized generic pathway.

What formulation and method-of-use rights are important?

The most commercially relevant patent categories are likely to include:

  • The zidesamtinib chemical compound and related salts.
  • Pharmaceutical compositions containing zidesamtinib.
  • Treatment of ALK-positive cancers.
  • Treatment of tumors with specific ALK resistance mutations.
  • Treatment of patients with central nervous system metastases.
  • Dosing regimens and combination therapies.
  • Use after prior treatment with another ALK inhibitor.

Composition-of-matter protection is normally the most valuable layer because it can block competing products using the same active molecule. Method-of-use patents may be narrower and more vulnerable to design-around strategies, although mutation-specific claims can protect valuable post-treatment niches.

When could zidesamtinib lose exclusivity?

There is no reliable commercial loss-of-exclusivity date until the relevant issued patents, patent-term adjustments, and any future FDA approval date are established. A projected expiry based only on the earliest filing date would not provide a complete market-exclusivity analysis.

Generic entry would also require an approved reference product and an abbreviated approval pathway. Neither exists today. For a small-molecule drug, a future ANDA applicant could challenge listed patents through Paragraph IV certification after an FDA-approved reference product is listed in the Orange Book.

What litigation, licensing, and settlement activity affects zidesamtinib?

No major public patent litigation, Paragraph IV dispute, or settlement agreement involving zidesamtinib has been reported in the development-stage record. The absence of litigation is expected because the drug is not yet approved and has no Orange Book listing.

No major out-licensing transaction for zidesamtinib has established an external valuation benchmark. Nuvalent retains the principal economic exposure to the asset based on its public development structure.

A future licensing or acquisition transaction would likely depend on:

  • Clinical activity after prior lorlatinib.
  • Central nervous system efficacy.
  • Safety differentiation.
  • Regulatory designation.
  • Remaining patent term.
  • Commercial rights by territory.
  • Manufacturing scalability and supply economics.

What market dynamics will determine zidesamtinib’s commercial potential?

Zidesamtinib’s market opportunity is shaped by treatment sequencing rather than simple diagnosis volume.

The post-lorlatinib market is the key test

If zidesamtinib is active after lorlatinib, it could address a high-value salvage population with limited targeted options. If its activity is mainly confined to patients who have not received the newest-generation ALK inhibitors, its commercial positioning would be less distinct.

CNS control is commercially important

ALK-positive NSCLC has a high risk of brain metastases. A product with durable intracranial activity can influence prescribing even when systemic response rates are similar. CNS efficacy also supports treatment continuity and may reduce reliance on local radiation or chemotherapy in selected patients.

Safety can support switching and longer treatment

Lorlatinib’s clinical use is influenced by adverse events including central nervous system effects, lipid abnormalities, weight changes, and other tolerability concerns. Zidesamtinib does not need to eliminate these risks, but a cleaner safety profile could support use after prior ALK therapy and potentially create a maintenance or switch opportunity.

Physician adoption will depend on sequencing evidence

Oncologists will require evidence that zidesamtinib provides benefit after defined prior therapies. Mutation testing, liquid biopsy adoption, treatment guidelines, and access to broad next-generation sequencing will affect uptake.

What generic launch risks exist for zidesamtinib?

No generic launch risk exists before approval. After approval, the main risks would be:

  1. Paragraph IV patent challenges.
  2. Narrow method-of-use protection.
  3. Earlier-than-expected patent expiry.
  4. Competing ALK inhibitors reaching the market first.
  5. Label limitations that exclude major treatment settings.
  6. Failure to secure broad composition or formulation claims.
  7. Physician preference for established products despite comparable efficacy.

Manufacturing is unlikely to be the primary long-term barrier if zidesamtinib is a conventional small molecule. The stronger barriers are clinical differentiation, regulatory approval, patent durability, and commercial access.

How strong is the current zidesamtinib investment case?

The investment case is asymmetric. The upside is tied to a differentiated treatment for resistant ALK-positive NSCLC, a market where molecularly defined patients can support premium pricing and extended therapy. The downside is concentrated in clinical failure, insufficient post-lorlatinib activity, adverse-event findings, or a crowded ALK treatment sequence.

Value driver Current assessment
Product revenue None
Regulatory risk High; investigational asset
Market need Meaningful in resistant ALK-positive NSCLC
Competitive intensity High
CNS differentiation Central to commercial success
Patent visibility Developing; no Orange Book protection yet
Financing dependence High before approval
Generic risk None before approval; future risk depends on issued claims
Partnership value Potentially high if clinical differentiation is confirmed

Key Takeaways

  • Zidesamtinib is an investigational ALK inhibitor developed by Nuvalent for ALK-positive NSCLC.
  • It has no FDA approval, product revenue, Orange Book listing, generic competition, or Paragraph IV litigation.
  • Its commercial value depends on activity after prior ALK inhibitors, especially lorlatinib.
  • Brain penetration and a differentiated safety profile are the core product claims.
  • Nuvalent’s financial trajectory remains loss-making and development-driven until a potential approval or strategic transaction.
  • The most important upcoming value inflection points are response durability, intracranial activity, safety, registrational-trial design, and regulatory engagement.
  • Patent value will depend on surviving composition-of-matter and method-of-use claims, but a definitive expiry date is not established by the public development-stage record.

FAQs

Is zidesamtinib approved by the FDA?

No. Zidesamtinib remains an investigational therapy and has not received FDA marketing approval.

Does zidesamtinib have an Orange Book patent listing?

No. An Orange Book listing requires an approved reference product. Zidesamtinib has no approved reference product.

Is zidesamtinib a competitor to lorlatinib?

Yes. It is being developed for the same broad ALK-positive NSCLC treatment ecosystem, with its clearest potential differentiation in patients whose disease has progressed after prior ALK inhibitors.

Will zidesamtinib generate revenue for Nuvalent?

It generates no product revenue before approval. Revenue would begin only after regulatory approval, commercial launch, payer access, and prescription uptake.

What is the biggest commercial risk for zidesamtinib?

The largest risk is failure to show durable clinical and intracranial benefit after prior next-generation ALK inhibitors. Without that differentiation, zidesamtinib would enter a crowded market against established therapies.

References

ClinicalTrials.gov. (n.d.). A study of NVL-655 in patients with advanced solid tumors harboring genetic changes in ALK. U.S. National Library of Medicine. https://clinicaltrials.gov/

Nuvalent, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=1823882

Nuvalent, Inc. (n.d.). Pipeline and corporate presentations. https://ir.nuvalent.com/

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/  

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.